Clinical Trials

Ongoing Trials

Here you will find a list of all ongoing trials in NMSG with a short description and contact details for the principal investigator of the study. All NMSG members have access to the full protocol in the member area.

NMSG 22/14 – Magnolia

Principal investigator: Thomas Lund

Results:

Potential value of pre-planned imaging of bone disease in multiple myeloma, PMID: 37419876
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease, PMID: 38622134
A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma, PMID: 35113466

NMSG 23/15 – IRD Study

Principal investigator: Raija Silvennoinen

Results:

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group, PMID: 38473382

NMSG 25/16 - The CONPET study

Principal investigator: Fredrik Schjesvold

Results:

NMSG 26/19 - COBRA

Principal investigator: Valdas Pečeliūnas

Synopsis

NMSG 28/19 - PERSEUS

Principal investigator: Annette Vangsted

Results:

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

NMSG 29/21 - SABLE

Principal investigator: Ida Kristensen

NMSG 30/21 - REST

Principal investigator: Frida Askeland

Results:

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial

NMSG 31/21 - REMNANT

Principal investigator: Fredrik Schjesvold

NMSG 32/23 - SHIELD

Principal investigator: Agoston Gyula Szabo

NMSG 33/23 - TALTEC

Principal investigator: Diana Loigom

NMSG 34/19 - NOR-ASCT

Principal investigator: Kari Lenita Falck Moore

Results:

Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group

NMSG 35/19 - TOP-75

Principal investigator: Kari Lenita Falck Moore

Results:

Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

NMSG 36/20 - CA in MM

Principal investigator: Sigrun Thorsteinsdottir

Results:

Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group

NMSG 37/22 - TOP85

Principal investigator: TBD

Former and finalized studies

MP-T + Thal maintenance vs. MP-R + Rev maintenance as first line treatment in elderly newly diagnosed (phase III, NMSG-HOVON-study)

Publications:

Zweegman et al, Blood. 2016 Mar 3;127(9):1109-16 [https://www.ncbi.nlm.nih.gov/pubmed/26802176]

NOP in refractory myeloma (phase II) and newly diagnosed myeloma (phase III)

Publications:

Gimsing et al. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG). Br J Haematol. 1991 Jan;77(1):73-9.

Wisløff et al. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol. 1992 Feb;48(2):70-4.

Keldsen et al. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).Eur J Haematol. 1993 Aug;51(2):80-5.

MP vs. MP+IFNa (phase III)

Publications:

Wisløff F, et al.Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996 Mar;92(3):604-13. DOI:10.1046/j.1365-2141.1996.352889.x

Wisløff F, et al.Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol. 1996 Aug;94(2):324-32. DOI:10.1046/j.1365-2141.1996.d01-1802.x

Wisløff et al. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997 Apr;97(1):29-37. DOI: 10.1046/j.1365-2141.1997.222667.x

High-dose chemotherapy + stem cell support in patients < 60 years (vs. historical control)

Publications:

Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000 Jan 1;95(1):7-11.

Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006 May;133(4):389-96. DOI: 10.1111/j.1365-2141.2006.06042.x

High-dose chemotherapy + stem cell support in patients < 65 years (vs. historical control)

Publications:

Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]

Induction chemotherapy VAD vs. Cy-Dex (phase III)

Publications:

Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]

Induction chemotherapy Cy-Fludarabin-Dex vs. Cy-Dex (phase II)

Publications:

HE Johnsen, LM Knudsen, AK Mylin, P Gimsing, H Gregersen, N Abildgaard, JL Nielsen, N Frost Andersen, T Plesner, A Vangsted, T Mourits-Andersen. Impaired stem cell mobilization by adding fludarabine to cyclophophamide-dexamethason induction therapy in multiple myeloma patients. Report from the NMSG #13/03 sponsored randomized, placebo controlled trial. Hematology Reviews, vol 1; 62-64. 2009

MP vs. MP-T in elderly newly diagnosed (phase III)

Publications:

Waage et al, Blood. 2010 Sep 2;116(9):1405-12 [https://www.ncbi.nlm.nih.gov/pubmed/20448107]

Pamidronate 90 mg vs. 30 mg in bone protection (phase III)

Publications:

Gimsing et al Lancet Oncol. 2010 Oct;11(10):973-82 [https://www.ncbi.nlm.nih.gov/pubmed/20863761]

Bortezomib-Dex vs. Thalidomide-Dex in first relapse (phase III)

Publications:

Hjorth et al, Eur J Haematol. 2012 Jun;88(6):485-96. [https://www.ncbi.nlm.nih.gov/pubmed/22404182]

Bortezomib consolidation vs. no consolidation post-ASCT (phase III)

Publications:

Mellqvist et al, Blood. 2013 Jun 6;121(23):4647-54. [https://www.ncbi.nlm.nih.gov/pubmed/23616624]

Bortezomib-Dex re-induction followed by Bortezomib+Melfalan conditioning and ASCT in first relaps after prior ASCT (phase II)

Publications:

Gimsing et al, Bone Marrow Transplant. 2015 Oct; 50(10): 1306–1311 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598614/]